Search

Displaying results 6521 - 6530 of 6949 in total
  1. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid formation. It also has an effect on...

  2. Drug

    Baminercept

    go.drugbank.com/drugs/DB06576
    Investigational

  3. Drug

    7-beta-Hydroxyepiandrosterone

    go.drugbank.com/drugs/DB06622
    Investigational

  4. Drug

    Rostaporfin

    go.drugbank.com/drugs/DB06659
    Investigational

  5. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  6. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, result...

  7. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. Because...

  8. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constricti...

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  9. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.

  10. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT)).